Somaxon Pharmaceuticals — BIO CEO & Investor Conference 2010
26 slides from Somaxon Pharmaceuticals's conference presentation, Feb 8, 2010

Slide 1: Somaxon Pharmaceuticals, Inc. BIO CEO & Investor Conference
Somaxon Pharmaceuticals, Inc. February 8, 2010 BIO CEO & Investor Conference Nasdaq: SOMX

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about our business, including results of our clinical trials, potential regulatory approval for our product candidate, development timelines, future financial results and events that have not yet occurred. Pharmaceutica

Slide 3: Somaxon: A Focus on CNS
Somaxon: A Focus on CNS Specialty pharmaceutical company Core asset: Silenor for insomnia NDA under FDA review - Class 1 Resubmission FDA Action date: March 21, 2010 Partnering discussions ongoing NASDAQ: SOMX

Slide 4: Focused Strategy Reduces Risk
Focused Strategy Reduces Risk Develop and Commercialize Highly Differentiated Products Target late-stage or currently marketed assets Address unmet medical need and patient dissatisfaction Leverage development, regulatory and commercial expertise Deploy a U.S. Commercial Organization Focus on the CN

Slide 5: Silenor for Insomnia Near-term Opportunity
Silenor for Insomnia Near-term Opportunity "Launch Ready" Marketing Campaign: 2H 2010 possible launch with partner Product profile supports attractive revenue estimates Changing insomnia market dynamics ? commercial upside Differentiated Mechanism of Action H1 specificity vs. GABA or melatonin Stron

Slide 6: Pharmaceuticals
\\ a aS Pharmaceuticals

Slide 7: U.S. Insomnia Market: Large and Dissatisfied
U.S. Insomnia Market: Large and Dissatisfied 70 million people in the U.S. suffer from insomnia Market remains under-diagnosed, under-treated, and dissatisfied 14 million (20%) are currently on Rx treatment 9 million (67%) are not satisfied 56 million utilize OTC and other remedies Current options f

Slide 8: Market Dissatisfied with Current Options
Poorly/Not at All Controlled Completely/Well Controlled Somewhat Controlled 4th Qtr East 39 12 49 20.4 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 Market Dissatisfied with Current Options Somaxon Market Research, 2006; n = 451 "How well would you say your insomnia/sleep problem is controlled?"

Slide 9: Room for Improvement
Room for Improvement Patients Not Satisfied With Rx GABA Products Less Time to Get to Sleep Woke Less During Night Slept Longer Felt Rested on Waking Felt Better Overall East 76.2 60.8 48.6 47 48.1 % of Patients Taking "Z Drugs"* <50% report sleeping longer, feeling rested, or feeling better overall

Slide 10: Sleep Maintenance is Primary Issue
Sleep Maintenance is Primary Issue 65% 35% Sleep Problem in Past Month At Least a Few Nights/Week 49% Woke Unrefreshed 42% Frequent Nocturnal Awakenings 29% Early Morning Awakenings 26% Difficulty Falling Asleep National Sleep Foundation. Summary of findings: 2008 Sleep in America poll. n = 1760 res

Slide 11: Large and Accessible Market
Large and Accessible Market Over 70 million TRx's in the U.S. 2009 Demographics favorable for continued year over year growth Prescription growth accelerates with the introduction of novel, differentiated products Patients want new options 90% would be willing to try Silenor 70% would ask for it on

Slide 12: Changing Market Dynamics Create Opportunities
Changing Market Dynamics Create Opportunities Solid "window of opportunity" for new treatments A void of new and differentiated insomnia treatments since 2006 No "novel" compounds expected to launch in near term Clinical and Regulatory setbacks for several drugs in development Somaxon estimates seve

Slide 13: A Novel Treatment for Insomnia: Silenor
A Novel Treatment for Insomnia Silenor

Slide 14: Starting With a Differentiated Mechanism of Action
Starting With a Differentiated Mechanism of Action Histamine (H1) is one of several waking neuro-transmitters important in the arousal system Silenor has high affinity for H1 receptors Twenty-fold more potent than diphenhydramine, and significantly more selective Silenor has significant effects at n

Slide 15: Finishing With a Strong Clinical Profile
Finishing With a Strong Clinical Profile Six controlled clinical trials completed Adult and elderly populations Chronic and transient insomnia Primary efficacy endpoint achieved statistical significance in each of Phase 2 and 3 studies Comprehensive Phase 1/Non-clinical program completed Cardiac stu

Slide 16: Silenor: Just What the Patient Ordered
Silenor: Just What the Patient Ordered Treat sleep maintenance insomnia The most significant insomnia complaint 7-8 hours of sleep with Silenor Prevention of early morning awakenings - a full night's sleep Unique potential positioning for Silenor Sleep onset (<30 min) Clinically meaningful Proposed

Slide 17: Silenor Commercialization
Silenor Commercialization Silenor

Slide 18: A Refreshingly Different Sleep Solution
A Refreshingly Different Sleep Solution Silenor Commercialization

Slide 19: Silenor Branding Platform
Silenor Branding Platform Brand Identity - Refreshingly Different Key Messages - A full 7-8 hours of sleep - Safe for chronic use - Non-addicting, no abuse potential - Placebo-like side effect profile - No residual hangover effect - Unique MOA Positioning - -Silenor is first-line therapy for sleep m

Slide 20: "Plan to Win"
"Plan to Win" Capitalize on the Changing Market Dynamics Competitor "turbulence" Lack of differentiated insomnia treatments Shift from expensive DTC strategy Launch with a Competitive Share of Voice with a Partner Target high value physicians Utilize non-personal promotional efforts to leverage into

Slide 21: Somaxon Pharmaceuticals, Inc. Corporate Summary
Somaxon Pharmaceuticals, Inc. Corporate Summary

Slide 22: Strategic Collaboration for Silenor
Strategic Collaboration for Silenor GOALS Successful Silenor launch in 2H 2010 Build a focused Somaxon commercial organization Maximize shareholder value Traditional licensing with co-promotion rights Co-promotion with shared revenues and costs M&A to gain access to sales infrastructure/ products

Slide 23: Financials
Financials Cash, cash equivalents & marketable securities (12/31/09) Shares outstanding Fully diluted shares $5.2 MM* 23.1 MM 34.9 MM * Sufficient to fund operations through 2Q 2010 based upon current operating plan

Slide 24: Near-Term Priorities
Near-Term Priorities Obtain regulatory approval for Silenor NDA re-submission accepted March 21, 2010 FDA action date Partner Silenor Ongoing dialogue with multiple parties Build commercial infrastructure Execute post-approval Launch Silenor in U.S. in 2H 2010

Slide 25: Somaxon Value Proposition
Somaxon Value Proposition Silenor Highly differentiated insomnia treatment Favorable market dynamics "Launch Ready" campaign following regulatory approval Attractive revenue potential Experienced management team Significant commercial launch experience Building a focused commercial organization Capa

Slide 26: Thank You!
Somaxon Pharmaceuticals, Inc. Thank You!
Source: SEC EDGAR · 8-K filed Feb 8, 2010
More decks from Somaxon Pharmaceuticals Inc
Technical Presentation (June 2011)17 slides · Jun 15, 2011
Investor Presentation (May 2011)18 slides · May 24, 2011
13th Annual BIO CEO & Investor Conference (February 2011)22 slides · Feb 14, 2011
UBS Global Life Science Conference 201022 slides · Sep 21, 2010
BMO Capital Markets 10th Annual Focus on Healthcare Conference (August 2010)29 slides · Aug 5, 2010
Rodman & Renshaw 11th Annual Healthcare Conference (September 2009)32 slides · Sep 8, 2009